Objective To investigate the prognostic differences and decision-making role in postoperative radiotherapy of four molecular subtypes in pT1-2N1M0 stage breast cancer. Methods The clinicopathological data of 1526 patients with pT1-2N1M0 breast cancer treated at West China Hospital of Sichuan University between 2008 and 2018 were retrospectively analyzed. χ2 test was used to compare the clinicopathological features among patients with different molecular subtypes. Kaplan-Meier survival analysis and log-rank test were used to draw the survival curves and compare the overall survival (OS) and breast cancer-specific survival (BCSS) among patients with different molecular subtypes. Cox regression model was used to determine the influencing factors of OS of patients after radical mastectomy. Results Among the 1526 patients with pT1-2N1M0 breast cancer, there were 674 cases (44.2%) of Luminal A subtype, 530 cases (34.7%) of Luminal B subtype, 174 cases (11.4%) of human epidermal growth factor receptor 2 (Her-2) overexpression subtype, and 148 cases (9.7%) of triple-negative subtype. The 5-year OS rates of Luminal A, Luminal B, Her-2 overexpression and triple negative patients were 98.6%, 94.3%, 95.5% and 91.2%, respectively (χ2=11.712, P=0.001), and the 5-year BCSS rates were 99.3%, 94.6%, 95.5% and 92.5%, respectively (χ2=18.547, P<0.001). Multiple Cox regression analysis showed that menstrual status [hazard ratio (HR)=0.483, 95% confidence interval (CI) (0.253, 0.923), P=0.028] and whether endocrine therapy [HR=2.021, 95%CI (1.012, 4.034), P=0.046] were prognostic factors for the 5-year OS rate of breast cancer patients after radical mastectomy (P<0.05). However, it failed to reveal that Luminal subtypes and postoperative radiotherapy were prognostic factors for the 5-year OS rate (P>0.05). Conclusions In pT1-2N1M0 breast cancer patients, the 5-year OS rate and 5-year BCSS rate in triple-negative patients are the lowest. The relationship between Luminal classification, postoperative radiotherapy and survival in patients after radical mastectomy needs further study in the future.
【Abstract】Objective To introduce the current studies of the role of vascular endothelial growth factorC (VEGFC) and VEGFD in lymphangiogenesis and lymph node metastasis of gastrointestinal neoplasma. Methods The related literatures in recent 5 years were reviewed. Results The growth factors VEGFC and VEGFD enhance lymphangiogenic metastasis of gastrointestinal neoplasma with the property of angiogenesis and lymphangiogenesis. In gastric adenocarcinoma, VEGFC mRNA and tissue protein expression correlate with lymphatic invasion, lymph node metastasis, venous invasion and reduced 5year survival rates. The role of VEGFC in esophageal squamous cancer and colorectal cancer and VEGFD in colorectal cancer is not certain, with conflicting reports in the published literatures.Conclusion The VEGFC, VEGFD/VEGFR3 signal pathway may become the ideal target for inhibition of tumor proliferation and metastases, antilymphangiogenesis therapy may be a novel potential strategy in tumor biological therapy.
目的:探讨雌激素饥饿对肿瘤坏死因子相关凋亡诱导配体(TRAIL)诱导乳腺癌细胞MCF-7凋亡的影响及作用机制。〖HTH〗方法〖HTSS〗:MCF-7细胞培养贴壁之后,用雌激素饥饿处理后加入TRAIL,用荧光染料Hoechst染色法检测细胞的凋亡,用细胞计数法检测细胞的存活。在雌激素饥饿处理MCF-7细胞后,收集对照和饥饿组蛋白用Western blot法检测相关的蛋白表达。〖HTH〗结果〖HTSS〗:单独使用雌激素饥饿处理或者单独使用TRAIL处理乳腺癌细胞MCF-7都能诱导细胞凋亡,但是它们诱导凋亡的活性较小,两种方法联合使用可以极大地增加诱导细胞凋亡的活性(Plt;0.001)。雌激素饥饿处理后的乳腺癌细胞,死亡受体5(DR5)表达上调。〖HTH〗结论〖HTSS〗:乳腺癌细胞MCF-7对TRAIL敏感度不高,雌激素饥饿可以增加TRAIL诱导乳腺癌细胞凋亡的活性,DR5与雌激素饥饿诱导TRAIL活性增加相关。
目的 初步探讨影响男性乳腺癌患者预后的因素。 方法 收集2003年1月－2011年12月经病理确诊、接受治疗、临床资料较完整的36例男性乳腺癌患者的临床资料。采用对数秩检验和Cox回归分析影响男性乳腺癌患者预后的因素。 结果 36例患者无进展生存期（PFS）为3～95个月，中位PFS为45个月。单因素分析显示：肿瘤直径（P=0.001）、阳性淋巴结（P=0.001）、TNM分期（P＜0.001）、手术方式（P=0.001）是影响预后的因素。多因素分析显示：阳性淋巴结（P=0.024）和TNM分期（P=0.022）是影响预后的主要因素。 结论 阳性淋巴结和TNM分期是影响预后的主要因素，以手术为主的综合治疗模式是提高男性乳腺癌患者生存率的重要措施。
Breast cancer is a malignancy with the highest incidence and mortality rate among women in the world. The current treatment methods include surgery, chemotherapy, radiotherapy, endocrine therapy and targeted therapy. Triple negative breast cancer (TNBC) has high manignant behavior and poor prognosis, lacks specific treatment targets, thus resulting in few effective treatment modalities. The emergence of immunotherapy has provided hopes for TNBC. The efficacy of immunocheckpoint inhibitors in neoadjuvant treatment of early TNBC and first-line treatment of programmed death-ligand 1 positive metastatic TNBC. Therefore, this article reviews the researches of immunocheckpoint inhibitors in the treatment of early and advanced breast cancer.
In the process of solid tumor transformation, the expression of claudins is often dysregulated. Claudins are involved in almost all aspects of tumor biology and steps of tumor development, suggesting that they have the potential to be diagnostics, and prognostic biomarkers and therapeutic targets. Current studies have found that Claudin18.2 is overexpressed in gastric cancer, pancreatic cancer, ovarian cancer and other diseases. Targeted anti-tumor therapy based on Claudin 18.2 has become a research hotspot recently. Therefore, this article reviews the basic structural characteristics of Claudin18.2, its expression in various malignant solid tumors, the progress of research and application, and prospect.
Objective To observe and preliminarily explore the effects of Deferasirox (DFX) on lipid peroxidation and ferroptosis in human retinal endothelial cells (HREC). MethodsA cell experimental study. Divided the in vitro cultured HREC into normal glucose (NG) group, high glucose (HG) group, NG+DFX group, HG+DFX group, NG+DFX+ferric ammonium citrate (FAC) group, and HG+DFX+FAC group. Light microscope was used to observe the morphology of the cells; cell proliferation was detected by Cell Counting Kit-8 assay, and Calcein-AM staining was used to detect the unstable iron pool (LIP) content; enzyme-linked immunosorbent assay reader was used to detect the reactive oxygen species (ROS), malondialdehyde (MDA), glutathione (GSH), and oxidized glutathione (GSSG); Western blot was used to detect the relative protein expression of Glutathione Peroxidase 4 (GPX4) and Solute Carrier Family 7 Member 11 (SLC7A11). Two-tailed Student t test was used for comparison between the two groups; one-way ANOVA was used for comparison between multiple groups. ResultsCompared with the HG group and the HG+DFX+FAC group, the cell proliferation rate and the contents of GSH and the relative protein expression of GPX4, and SLC7A11 in the HG+DFX group were significantly increased, and the differences were statistically significant (F=150.70, 21.02, 26.09, 52.62; P＜0.001). The contents of LIP, ROS, MDA, and GSSG were significantly decreased, and the differences were statistically significant (F=807.20, 16.94, 31.62, 19.21; P＜0.001). ConclusionsHigh glucose significantly induces an increase in LIP, lipid peroxidation, and ferroptosis in HREC. Deferasirox inhibits lipid peroxidation and ferroptosis in HREC by downregulating LIP levels.
目的:探讨表没食子儿茶素没食子酸酯(EGCG)对乳腺癌细胞MCF7生长的影响及对乳腺癌细胞MDAMB231迁移的影响。方法:MCF7细胞培养贴壁之后,加入EGCG处理,2d后收集蛋白,采用Western Blot检测磷酸化p38丝裂原活化蛋白激酶(phosphop38MAPK)的表达;同样处理后收集活细胞,用细胞计数法检测细胞的存活;取对数生长期的MDAMB231细胞,分至6孔板培养,使用EGCG处理后,采用细胞划线法探测乳腺癌细胞的迁移。结果:使用EGCG处理乳腺癌细胞后,phosphop38MAPK的表达降低,EGCG处理乳腺癌细胞4d后其增殖率降低50%,迁移活性降低。结论:EGCG处理乳腺癌细胞能抑制肿瘤细胞的生长以及迁移,这与p38MAPK信号通路相关。